Paz Corp S.A. (SNSE:PAZ)

CTI BioPharma Income Statement

Financials in millions CLP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	171,658	146,724	146,042	148,807	105,529	58,007
Revenue Growth (YoY)	13.43%	0.47%	-1.86%	41.01%	81.92%	-61.31%
Cost of Revenue	123,280	105,208	100,788	89,500	66,130	37,879
Gross Profit	48,379	41,515	45,254	59,307	39,399	20,127
Selling, General & Admin	21,411	19,183	16,891	13,935	13,835	8,298
Other Operating Expenses	-181.3	-	-	-569.3	-331.97	-118.55
Operating Expenses	21,791	20,279	17,981	14,191	14,235	8,878
Operating Income	26,588	21,237	27,273	45,116	25,164	11,250
Interest Expense	-6,740	-7,036	-4,929	-1,775	-503.93	-392.07
Interest & Investment Income	320.57	1,057	1,770	1,965	324.95	542.64
Earnings From Equity Investments	1,527	2,287	1,061	894.66	1,069	-595.65
Currency Exchange Gain (Loss)	1.75	-19.24	-94.49	52.83	279.05	54.41
Other Non Operating Income (Expenses)	-4,661	-4,273	-1,756	-3,131	2,499	527.86
EBT Excluding Unusual Items	17,037	13,253	23,325	43,121	28,833	11,387
Impairment of Goodwill	-65.89	-65.89	-68	-145.8	-	-
Gain (Loss) on Sale of Assets	-18.3	-10.21	21.41	3.07	16.62	-
Pretax Income	16,925	13,176	23,278	43,017	28,849	11,387
Income Tax Expense	832.74	-283.21	1,857	1,265	4,023	631.61
Earnings From Continuing Operations	16,092	13,460	21,421	41,752	24,826	10,755
Earnings From Discontinued Operations	-	-	-	-298.87	-	-
Net Income to Company	16,092	13,460	21,421	41,453	24,826	10,755
Minority Interest in Earnings	130.11	414.47	-2,162	-3,405	-1,785	-1,088
Net Income	16,222	13,874	19,259	38,048	23,041	9,667
Net Income to Common	16,222	13,874	19,259	38,048	23,041	9,667
Net Income Growth	-2.15%	-27.96%	-49.38%	65.14%	138.34%	-60.90%
Shares Outstanding (Basic)	283	283	283	283	283	283
Shares Outstanding (Diluted)	283	283	283	283	283	283
Shares Change (YoY)	0.04%	-	-	-	-	-
EPS (Basic)	57.23	48.96	67.96	134.27	81.31	34.11
EPS (Diluted)	57.23	48.96	67.96	134.27	81.31	34.11
EPS Growth	-2.19%	-27.96%	-49.39%	65.13%	138.38%	-60.91%
Free Cash Flow	41,682	-29,858	11,665	-5,066	-41,979	-10,157
Free Cash Flow Per Share	147.06	-105.37	41.16	-17.88	-148.14	-35.84
Dividend Per Share	15.000	15.000	30.000	42.000	33.000	17.000
Dividend Growth	-50.00%	-50.00%	-28.57%	27.27%	94.12%	-37.04%
Gross Margin	28.18%	28.29%	30.99%	39.86%	37.34%	34.70%
Operating Margin	15.49%	14.47%	18.68%	30.32%	23.85%	19.39%
Profit Margin	9.45%	9.46%	13.19%	25.57%	21.83%	16.66%
Free Cash Flow Margin	24.28%	-20.35%	7.99%	-3.40%	-39.78%	-17.51%
EBITDA	27,030	21,733	27,821	45,437	25,429	11,578
EBITDA Margin	15.75%	14.81%	19.05%	30.53%	24.10%	19.96%
D&A For EBITDA	442.63	495.77	547.93	320.64	264.16	328.16
EBIT	26,588	21,237	27,273	45,116	25,164	11,250
EBIT Margin	15.49%	14.47%	18.68%	30.32%	23.85%	19.39%
Effective Tax Rate	4.92%	-	7.98%	2.94%	13.94%	5.55%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.